A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 and 400 mcg o.d.) in patients with chronic obstructive pulmonary disease using formoterol (12 mcg b.i.d.) as an active control.

Trial Profile

A 52-week treatment, multicenter, randomized, double-blind, double dummy, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 and 400 mcg o.d.) in patients with chronic obstructive pulmonary disease using formoterol (12 mcg b.i.d.) as an active control.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 23 May 2011

At a glance

  • Drugs Formoterol; Indacaterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 23 May 2011 This trial is recruiting in Great Britain and has completed in Germany and discontinued in Sweden.
    • 17 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top